Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 6/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPD | P32754 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6718911 | 0.90 | PTGS2 (0.44) | PTGER1PTGS2PTGS1AKR1B1 | |
| SCHEMBL6721343 | 0.89 | PTGS2 (0.49) | PTGER1PTGS2PTGS1AKR1B1 | |
| SCHEMBL6723207 | 0.87 | PTGS2 (0.44) | PTGER1PTGS2PTGS1 | |
| SCHEMBL6722884 | 0.87 | PTGS2 (0.49) | PTGER1PTGS2PTGS1MEN1ALDH1A1 | |
| SCHEMBL6722804 | 0.85 | PTGS2 (0.45) | PTGER1PTGS2PTGS1 | |
| SCHEMBL6725527 | 0.85 | PTGS2 (0.45) | PTGER1PTGS2PTGS1 | |
| SCHEMBL6721463 | 0.84 | PTGS2 (0.47) | PTGER1PTGS2PTGS1 | |
| SCHEMBL6718738 | 0.84 | PTGS2 (0.58) | PTGS2PTGS1 | |
| SCHEMBL6722719 | 0.82 | PTGS2 (0.44) | PTGER1PTGS2PTGS1 | |
| SCHEMBL6729503 | 0.82 | PTGS2 (0.51) | PTGER1PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGER1 18/4885PTGS2 5/4885PTGS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.